본문으로 건너뛰기
← 뒤로

Long-term outcomes of transanal endoscopic microsurgery for clinical complete response after neoadjuvant treatment in T2-3 rectal cancer.

Surgical endoscopy 2022 Vol.36(5) p. 2906-2913

González JEB, Lavernia HC, Fraga JGP, Lemus SQ

관련 도메인

📝 환자 설명용 한 줄

[BACKGROUND] Organ sparing by the transanal endoscopic microsurgery (TEM) procedure is a treatment for patients with locally advanced rectal cancer after chemoradiotherapy (CRT) and complete clinical

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA González JEB, Lavernia HC, et al. (2022). Long-term outcomes of transanal endoscopic microsurgery for clinical complete response after neoadjuvant treatment in T2-3 rectal cancer.. Surgical endoscopy, 36(5), 2906-2913. https://doi.org/10.1007/s00464-021-08583-y
MLA González JEB, et al.. "Long-term outcomes of transanal endoscopic microsurgery for clinical complete response after neoadjuvant treatment in T2-3 rectal cancer.." Surgical endoscopy, vol. 36, no. 5, 2022, pp. 2906-2913.
PMID 34231071

Abstract

[BACKGROUND] Organ sparing by the transanal endoscopic microsurgery (TEM) procedure is a treatment for patients with locally advanced rectal cancer after chemoradiotherapy (CRT) and complete clinical response (cCR).

[AIMS] To assess the surgical and long-term oncological outcomes of TEM for the treatment in T2-3 rectal cancer after CRT and cCR.

[METHODS] This study was a retrospective review of a prospective database of patients with rectal cancer who underwent TEM after CRT and cCR from April 2011 to March 2020.

[RESULTS] 52 patients underwent TEM during a period of 9 years. This group of patients included 27 females and 25 males. The median age was 62 (32-86) years, lesion size was 2.5 (1-4) cm, and lesion distance from the anal verge 7.3 (4-10) cm. Median operative time was 79.5 (25-120) min and hospital stay was 1 day (14 h-4 days). Morbidity rate was 13.5% and reoperation rate due to major complications was 3.8%. Final histological findings confirmed 34 (65.4%) patients with ypT0, 7 (13.5%), 6 (11.5%), and 5 (9.6%) patients with carcinoma ypT1, ypT2, and ypT3, respectively. After a median follow-up period of 86 (5-107) months, 1 (2.4%) patient had local recurrences and 3 (7.3%) distant metastases. The 5-year disease-free survival was 91.7% and 5-year overall survival 89.5%.

[CONCLUSION] Our experience has shown significant rates of ypT0 and ypT1 associated with excellent long-term results. Performing TEM to treat T2-3N0 rectal cancer after CRT and cCR appears to be an oncologically safe and effective procedure.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 microsurgery 미세수술 dict 2
기법 endoscopic 내시경 dict 2
합병증 anal verge scispacy 1
약물 chemoradiotherapy C0436307
Chemoradiotherapy
scispacy 1
약물 [BACKGROUND] Organ scispacy 1
약물 [RESULTS] 52 patients underwent TEM during scispacy 1
질환 cancer C0006826
Malignant Neoplasms
scispacy 1
질환 rectal cancer C0007113
Rectal Carcinoma
scispacy 1
질환 carcinoma ypT1 scispacy 1
질환 T2-3 rectal cancer scispacy 1
질환 carcinoma scispacy 1
질환 ypT3 scispacy 1

MeSH Terms

Chemoradiotherapy; Female; Humans; Male; Microsurgery; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Rectal Neoplasms; Retrospective Studies; Transanal Endoscopic Microsurgery; Treatment Outcome

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문